The Osiris Advantage
The technology being developed by Osiris Therapeutics, Inc. has shown significant advantages over other cellular therapies in development for the following reasons:
Availability – Over ten thousand treatments can be produced from a single donation.
Universal Compatibility – Products can be used in any patient without typing or matching.
Ease of Use – Treatment can be accomplished with a simple I.V. infusion or injection.
Intellectual Property – The Company has 49 issued U.S. patents, each having one or more foreign counterparts.
Stem Cell Availability
Osiris Therapeutics has distinguished itself from other companies and research institutions through manufacturing methods that allow rapid growth in a controlled fashion to produce billions of stem cells from a single donation. Once produced, the cells can be stored in a frozen state, ready to be used when they are needed.
The feasibility of manufacturing very large numbers of mesenchymal stem cells or MSCs in a controlled and regulated manner is a critical part of the Osiris plan. We have combined insights into cell production with a strategy for treating many patients with a single donation of MSCs. Assuming success in our product development and regulatory affairs, this approach should offer patients access to the stem cell treatments in a timely, cost-effective manner.
In both animal and human clinical studies, Osiris scientists and academic researchers have found that MSCs are generally not rejected by the host immune system. This unique feature eliminates the need to tailor MSCs based on donor matching and means that patients can forgo the harmful side effects of immune suppression.
MSCs are different from blood, organs and other stem cells. MSCs grown in culture from a single donor can be used to treat many patients. Because of the absence of rejection, these cells allow for the development of treatments applicable to all patients - a “universal” therapy.
Most other approaches to cell therapy depend on matching or amplifying the patient’s own cells. In contrast, MSCs offer the opportunity to treat patients in the acute setting, potentially within hours of the onset of symptoms. For example, a patient with an acute heart attack could be treated upon arrival at the emergency room, rather than waiting as individually customized cells are prepared over weeks or months, as is the case with other cell technologies.
Ease of Use
As part of the normal healing process, the body’s native MSCs residing in one’s bone marrow are attracted to sites of tissue damage. Osiris has harnessed this natural homing ability in its therapeutic MSCs such that they can be infused via standard intravenous or injection methods to treat conditions in various damaged areas of the body. For most applications, Osiris' MSCs are delivered to the hospital or clinic in a standard IV bag that staff are familiar with using.
Osiris has established a significant patent position in adult stem cell technology. The Company has committed to protect its intellectual property position and currently owns or has exclusive license to 49 issued U.S. patents, each having one or more foreign counterparts.